SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.
20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
For the month of March 2006
Commission File Number 000-31062
Oncolytics Biotech Inc.
(Translation of registrants name into
English)
Suite 210, 1167 Kensington Crescent NW
Calgary, Alberta, Canada T2N 1X7
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports
under cover Form 20-F or Form 40-F.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(1): o
Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a
Form 6-K if submitted solely to provide an attached annual report to security
holders.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(7): o
Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a
Form 6-K if submitted to furnish a report or other document that the registrant
foreign private issuer must furnish and make public under the laws of the
jurisdiction in which the registrant is incorporated, domiciled or legally
organized (the registrants home country), or under the rules of the home
country exchange on which the registrants securities are traded, as long as
the report or other document is not a press release, is not required to be and
has not been distributed to the registrants security holders, and, if
discussing a material event, has already been the subject of a Form 6-K
submission or other Commission filing on EDGAR.
Indicate by check mark whether by furnishing the information contained in this
Form, the registrant is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of
1934.
If Yes is marked, indicate below the file number assigned to the registrant
in connection with Rule 12g3-2(b): 82 -
|
|
|
|
|
210, 1167 Kensington Cr. N.W.
Calgary, Alberta
Canada T2N 1X7 |
For Immediate Release
Oncolytics Biotech Inc. Phase I Combination REOLYSIN®/Radiation
Clinical Trial Abstract Available on AACR Website
CALGARY, AB, March 3, 2006 Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY)
announced today that an abstract covering the preliminary results of a Phase I combination
REOLYSIN®/radiation clinical trial being conducted in the U.K. is available today on the American
Association for Cancer Research (AACR) website at www.aacr.org, and on the Oncolytics
website at www.oncolyticsbiotech.com. The abstract is entitled Phase I trial of
intratumoral administration of reovirus type 3 (Reolysin) in combination with radiation in patients
with advanced malignancies.
Early results of the study show that patients are experiencing local and systemic responses to the
combination of REOLYSIN® and radiation treatment, said Dr. Matt Coffey, Oncolytics Chief
Scientific Officer. We are pleased with these initial indications of activity, and look forward
to providing an update of interim study results at the AACR annual meeting.
An oral presentation covering more detailed interim results of the Phase I combination clinical
trial is scheduled to be delivered at the AACR annual meeting which runs April 1-5 in Washington,
D.C. The presentation will be delivered by Principal Investigator Dr. Kevin J. Harrington of the
Targeted Therapy Laboratory, The Institute of Cancer Research, Cancer Research UK Centre for Cell
and Molecular Biology and Honorary Consultant in Clinical Oncology at The Royal Marsden NHS
Foundation Trust, London, UK.
About Oncolytics Biotech Inc.
Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses
as potential cancer therapeutics. Oncolytics clinical program includes a variety of Phase I and
Phase I/II human trials using REOLYSIN®, its proprietary formulation of the human reovirus, alone
and in combination with radiation. For further information about Oncolytics, please visit
www.oncolyticsbiotech.com.
This press release contains forward-looking statements, within the meaning of Section 21E of
the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the
implication of the abstract and materials presented on the AACR website and at this meeting with
respect to REOLYSIN®, the Companys expectations related to the results of trials investigating
delivery of REOLYSIN®, and the Companys belief as to the potential of REOLYSIN® as a cancer
therapeutic, involve known and unknown risks and uncertainties, which could cause the Companys
actual results to differ materially from those in the forward-looking statements. Such risks and
uncertainties include, among others, the availability of funds and resources to pursue research and
development projects, the efficacy of REOLYSIN® as a cancer treatment, the success and timely
completion of clinical studies and trials, the Companys ability to successfully commercialize
REOLYSIN®, uncertainties related to the research and development of pharmaceuticals, uncertainties
related to the regulatory process and general changes to the economic environment. Investors should
consult the Companys quarterly and annual filings with the Canadian and U.S. securities
commissions for additional information on risks and uncertainties relating to the forward looking
statements. Investors are cautioned against placing undue reliance on forward-looking statements.
The Company does not undertake to update these forward-looking statements.
FOR FURTHER INFORMATION PLEASE CONTACT:
|
|
|
Oncolytics Biotech Inc.
|
|
The Equicom Group |
Cathy Ward
|
|
Nick Hurst |
210, 1167 Kensington Cr NW
|
|
20 Toronto Street |
Calgary, Alberta T2N 1X7
|
|
Toronto, Ontario M5C 2B8 |
Tel: 403.670.7377
|
|
Tel: 416.815.0700 ext.226 |
Fax: 403.283.0858
|
|
Fax: 416.815.0080 |
www.oncolyticsbiotech.com
|
|
nhurst@equicomgroup.com |
|
|
|
The Investor Relations Group
|
|
RenMark Financial Communications |
Damian McIntosh
|
|
John Boidman |
11 Stone St, 3rd Floor
|
|
2080 Rene Levesque Blvd. W. |
New York, NY 10004
|
|
Montreal, PQ H3H 1R6 |
Tel: 212.825.3210
|
|
Tel: 514.939.3989 |
Fax: 212.825.3229
|
|
Fax: 514.939.3717 |
dmcintosh@investorrelationsgroup.com
|
|
jboidman@renmarkfinancial.com |
-30-